Q-omics provides the consensus-scored GRHL3-AS1 profile across patient tissues and cancer cell-line models. GRHL3-AS1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GRHL3-AS1 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, GRHL3-AS1 RNA expression shows 13,931 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, LUAD, and TGCT as cancer lineages where GRHL3-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRHL3-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRHL3-AS1 survival associations across molecular data types. GRHL3-AS1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRHL3-AS1 RNA expression–survival associations across cancer types. High GRHL3-AS1 expression shows unfavorable associations in READ, but favorable associations in HNSC, UCS, UCEC, KIRP and LUSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GRHL3-AS1 RNA expression.
This table summarizes GRHL3-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for GRHL3-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRHL3-AS1 shows higher tumor expression in LUAD, LUSC, THCA, BLCA, COAD and HNSC. The LUAD box plot shows higher GRHL3-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.304, t-test p < 0.001).
This table shows molecular features associated with GRHL3-AS1 in patient tissues and cancer cell lines. In patient samples, GRHL3-AS1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
